Core Insights - Nuclear medicine is a crucial interdisciplinary field that combines nuclear physics, chemistry, biology, and medicine for diagnosis, treatment, and research using radioactive isotopes [1][2][4] - The market for diagnostic and therapeutic radioactive drugs in China has grown from 2.2 billion yuan in 2017 to 5.4 billion yuan in 2023, with projections of 7.1 billion yuan in 2024 and 9.3 billion yuan in 2025 [1][10] - The industry is experiencing a significant transformation from a niche technology to a core diagnostic tool for tumors and chronic diseases, marking the next decade as a golden development period [1][20] Industry Definition - Nuclear medicine involves the application of radioactive isotopes for medical diagnostics, treatment, and research, focusing on the distribution of radioactive drugs in the body to obtain physiological and pathological information [2][4] - The industry encompasses radioactive drugs, medical radiation sources, nuclear medicine imaging equipment, and radiation therapy devices [2] Development Environment - The Chinese government has been actively promoting the nuclear medicine industry through various policies, including the "Three-Year Action Plan for High-Quality Development of Nuclear Technology Application Industry (2024-2026)" [6][7] - Local governments, such as in Guangdong and Sichuan, have also introduced plans to accelerate the development of the nuclear medicine sector [6][7] Current Market Status - The nuclear medicine market in China is characterized by high market concentration, with a CR1 of 31.16%, CR2 of 50.01%, and CR3 of 53.69% [12] - The industry has seen significant advancements in technology and capabilities, transitioning from a lagging position to a competitive one [14] Competitive Landscape - Major players in the nuclear medicine market include China Nuclear Industry, East China Pharmaceutical, and Yuanda Medical, with East China Pharmaceutical holding the largest market share at 35.16% [16][18] - The market is structured into tiers, with several companies classified in the first and second tiers based on their registered capital [16] Future Trends - The nuclear medicine industry in China is poised for substantial growth due to increasing demand for precision medicine, new radioactive drug developments, and supportive policies [20] - The aging population and rising health management awareness are expected to drive explosive growth in diverse nuclear medicine services [20]

Core Insights - Nuclear medicine is a crucial interdisciplinary field that combines nuclear physics, chemistry, biology, and medicine for diagnosis, treatment, and research using radioactive isotopes [1][2][4] - The market for diagnostic and therapeutic radioactive drugs in China has grown from 2.2 billion yuan in 2017 to 5.4 billion yuan in 2023, with projections of 7.1 billion yuan in 2024 and 9.3 billion yuan in 2025 [1][10] - The industry is experiencing a significant transformation from a niche technology to a core diagnostic tool for tumors and chronic diseases, marking the next decade as a golden development period [1][20] Industry Definition - Nuclear medicine involves the application of radioactive isotopes for medical diagnostics, treatment, and research, focusing on imaging and radiotherapy [2][4] - The industry encompasses radioactive drugs, medical radiation sources, nuclear imaging equipment, and radiotherapy devices [2] Development Environment - The Chinese government has implemented various policies to support the nuclear medicine industry, including the "Three-Year Action Plan for High-Quality Development of Nuclear Technology Application Industry (2024-2026)" [6][7] - These policies aim to enhance innovation, expand clinical applications, and create new opportunities for related enterprises [6] Current Market Status - The nuclear medicine market in China is characterized by high market concentration, with a CR1 of 31.16%, CR2 of 50.01%, and CR3 of 53.69% [12] - The industry has seen significant technological advancements, moving from a lagging position to a competitive one [14] Competitive Landscape - Major players in the nuclear medicine market include China Dongfang, East Cheng Pharmaceutical, and Yuanda Medical, with East Cheng holding the largest market share at 35.16% [16][18] - The market is structured into tiers, with several companies classified in the first and second tiers based on their registered capital [16] Future Trends - The nuclear medicine industry in China is poised for substantial growth due to increasing demand for precision medicine, new drug development, and supportive policies [20] - The aging population and rising health management awareness are expected to drive explosive growth in nuclear medicine services [20]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 遠大醫藥集團有限公司 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00512 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 100,000,000,000 | HKD | | 0.01 HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 100,000,000,000 | HKD | | 0.01 HKD | | 1,000,000,000 | 本月底法定/註冊股本總額： HKD ...

Core Viewpoint - The nuclear medicine industry in China is experiencing a pivotal moment with the strategic partnership between YuanDa Pharmaceutical and IRE ELiT, enhancing the supply chain for medical-grade Ge-68/Ga-68 generators, which aligns with international standards and meets domestic regulatory requirements [1][7]. Industry Overview - The nuclear medicine sector is emerging as a new approach for cancer diagnosis and treatment, with a focus on drugs labeled with Lu-177 and Ga-68, where Ga-68 is crucial for developing next-generation PET imaging agents [2]. - The market for diagnostic and therapeutic radioactive drugs in China is projected to reach 9.3 billion yuan by 2025, growing at a compound annual growth rate (CAGR) of 22.7% to 26 billion yuan by 2030, indicating significant market potential [4]. Supply Chain Challenges - There is a current shortage in the supply of radioactive isotopes in China, primarily due to import monopolies. The short half-life of isotopes like Ga-68 necessitates a stable supply chain, making the local production of key isotopes essential for the industry's health [6]. - The collaboration with IRE ELiT aims to establish a reliable supply chain for Ga-68 generators, addressing clinical demand gaps in China [6][7]. Company Developments - YuanDa Pharmaceutical has established a comprehensive industry chain in nuclear medicine, covering research, production, sales, and regulatory qualifications, with a pipeline of 15 innovative products targeting various cancers [8][11]. - The company’s Chengdu facility, which received a Class A radiation safety license, is the world's first closed-loop platform for the entire nuclear medicine industry chain, with an investment exceeding 3 billion yuan [12]. - YuanDa's innovative product, SIR-Spheres Y-90 microspheres, has seen rapid growth, achieving nearly 500 million HKD in revenue in 2024, reflecting a year-on-year increase of over 140% [11]. Strategic Partnerships - The partnership with IRE ELiT will enable YuanDa to leverage its market capabilities to promote the registration, localization, and commercialization of Ga-68 generators in China, enhancing the availability of PET imaging technology [7][13]. - This collaboration is expected to serve as a foundation for localizing the nuclear medicine supply chain in China, improving industry resilience and safety [7][13].

我国核药产业发展迎来破局时刻！ （图源：弗若斯特沙利文） 据弗若斯特沙利文数据，2025年中国显像诊断和治疗用放射性药物市场规模预计将达93亿元，并将以22.7%的复合年增长率增至2030年的260亿元，市场空 间巨大。 （图源：弗若斯特沙利文） 与需求增长相对的是供应能力的短缺，目前我国核素供应仍存在进口垄断的问题。与此同时，鉴于以68Ga为代表的放射性核素具有半衰期较短的特性，因而 提升放射性药物的供应链稳定性尤为关键。因此，推动关键核素的规模化生产、构建可靠的供应链体系已不仅是药企发展的保障，更是推动我国核药产业健 康发展的关键因素。 在此背景下，远大医药布局比利时IRE ELiT锗-68/镓-68发生器，将为公司创新核药管线的临床及商业化奠定坚实的基础，并有望有效缓解我国临床需求缺 口。 智通财经APP获悉，在众多药企逐渐加码创新核药产品之时，核药龙头远大医药（00512）进一步夯实其核药产业布局优势，7月31日，远大医药宣布与IRE EliT公司（Institut National des Radioéléments / IRE ELiT）达成深度战略合作，获得其全球领先的药用级锗-68/镓-68（ ...

在作出所有合理查询后，按董事所知、所悉及所信，Outwit Investments 为一间于英属处女群岛注册成 立的有限责任公司，在完成股份转让前持有本公司 47.09% 的股权。 Outwit Investments 由远大(香港)国 际投资控股有限公司 (远大投资)持有99.85%股本权益。远大投资由中国远大集团有限责任公司 (中国远 大) 全资拥有，而中国远大由北京远大华创投资集团有限公司(北京远大华创)拥有93%权益。 东海资本为一间于香港注册成立的有限责任公司，是上海远大产融投资管理有限公司(上海产融)的全资 附属公司，而北京远大华创持有上海产融的70%股本权益。 北京远大华创由胡凯军先生(胡先生)控制及最终实益拥有。 智通财经APP讯，远大医药(00512)发布公告，董事会接获本公司控股股东 Outwit Investments Limited(Outwit Investments)通知，由于控股股东集团对本公司股权进行内部重组，Outwit Investments 于 2025年7月28日与本公司股东东海资本(香港)有限公司 (东海资本)订立股份转让协议，东海资本同意出 售而 Outwit In ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而 產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Grand Pharmaceutical Group Limited 遠大醫藥集團有限公司* ( 於百慕達註冊成立之有限公司 ) （股份代號: 00512） 自願性公告 董事會接獲本公司控股股東 Outwit Investments Limited（「Outwit Investments」）通知， 由於控股股東集團（定義見下）對本公司股權進行內部重組，Outwit Investments 於二零 二五年七月二十八日與本公司股東東海資本(香港)有限公司 （「東海資本」）訂立股份 轉讓協議，據此，東海資本同意出售而 Outwit Investments 同意收購本公司合共 224,373,091 股每股面值 0.01 港元之普通股（「股份」）（「股份轉讓」）。股份轉讓 之交割將於所有先決條件獲得滿足或被豁免以後的六十個營業日內進行。 緊隨上述股份轉讓完成後，Outwit Investments 將合共持有 1 ...

Group 1 - Nanshan Aluminum International (02610.HK) expects a mid-term net profit of approximately $225 million to $265 million for the six months ending June 30, 2025, compared to a net profit of about $159 million for the same period ending June 30, 2024 [1] - The increase in net profit is primarily attributed to an improvement in gross margin, driven by higher alumina prices and relatively stable unit production costs [1] - The average selling price of the company's products for the first half of 2025 is expected to be around $530 per ton, up from approximately $387 per ton in the first half of 2024, but lower than $561 per ton in the second half of 2024 [1] Group 2 - TCL Electronics (01070.HK) anticipates a year-on-year adjusted net profit growth of approximately 45% to 65% for the first half of 2025 [2] - Renrui Talent (06919.HK) expects a mid-term profit attributable to equity holders to increase by 66.7% to 94.1% [2] - China Rare Earth Holdings (03788.HK) reports an increase in total gold resources to 5.07 million ounces [2]

Core Viewpoint - The company, Yuan Da Pharmaceutical, has made significant advancements in its nuclear medicine sector, particularly with the innovative radiopharmaceutical TLX591 for prostate cancer treatment, which has received regulatory approval for international clinical trials, indicating strong potential for market growth and patient benefit [1][2][4]. Group 1: Product Development and Clinical Trials - TLX591, a radiolabeled monoclonal antibody, targets PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) and has shown significant advantages in treatment duration and radiation exposure compared to traditional therapies [2][3]. - The international multi-center Phase III clinical trial for TLX591 aims to enroll over 500 patients across multiple countries, including China, the US, Australia, New Zealand, and Europe, to evaluate its efficacy and safety [1][2]. - TLX591's companion diagnostic product, TLX591-CDx, has already been launched in several countries and is projected to achieve global sales of AUD 783 million in 2024, highlighting its commercial potential [3]. Group 2: Market Potential and Growth - The prostate cancer drug market is expected to grow at a compound annual growth rate (CAGR) of 8.3% to reach USD 37.6 billion by 2030, with China's market projected to grow at a CAGR of 21.8% to reach CNY 50.6 billion [4][5]. - The global prostate cancer diagnostics market is anticipated to exceed USD 11.5 billion by 2032, driven by increasing incidence rates [5]. - The success of Novartis' Pluvicto, which is expected to generate nearly USD 1.4 billion in revenue in 2024, reflects the industry's recognition of the significant market potential in nuclear medicine [5]. Group 3: Company Position and Innovations - Yuan Da Pharmaceutical has a robust pipeline with 15 innovative products in the nuclear medicine oncology sector, covering various cancers and including both diagnostic and therapeutic radiopharmaceuticals [6][9]. - The company has established itself as a leader in the nuclear medicine field, being one of the few globally to commercialize nuclear medicine products successfully [9]. - The newly operational nuclear medicine research and production base in Chengdu, which received a Class A radiation safety license, is set to enhance the company's capabilities in research, production, and sales across the entire nuclear medicine value chain [11][13].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內 容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 加入國際多中心 III 期臨床試驗的申請已獲中國藥監局默示許可 本公告乃遠大醫藥集團有限公司(「本公司」，連同其附屬公司統稱「本集團」)之董事 會(「董事會」)自願刊發。 董事會欣然公告，本集團用於治療前列腺癌的全球創新在研放射性核素偶聯藥物 「( RDC」) TLX591 (177Lu-rosopatamab tetraxetan)加入國際多中心 III 期臨床試驗的申請， 近日已獲得中華人民共和國國家藥品監督管理局(「中國藥監局」)默示許可，這是本集 團在核藥抗腫瘤診療領域的重要研發進展。本集團高度重視核藥產業全球化發展戰略， 積極推進創新核藥產品的全球化開發及註冊進程，並將持續深化本集團核藥產品管線的 全球化拓展。 該研究是一項前瞻性、隨機、對照、開放標籤、國際多中心的 III 期臨床試驗，擬在中 國、美國、澳大利亞、新西蘭及歐洲等全球多個國家和地區入組 500 余名患者，旨在評 估 TLX591 ...